Cargando…

Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis

Multiple Sclerosis (MS) is the most common demyelinating disease of man with over 400,000 cases in the United States and over 2.5 million cases worldwide. There are over 64,000 citations in Pubmed dating back as far as 1887. Much has been learned over the past 129 years with a recent burst in therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Soldan, Samantha S., Jacobson, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122906/
http://dx.doi.org/10.1007/978-3-319-33189-8_6
_version_ 1783515519517720576
author Soldan, Samantha S.
Jacobson, Steven
author_facet Soldan, Samantha S.
Jacobson, Steven
author_sort Soldan, Samantha S.
collection PubMed
description Multiple Sclerosis (MS) is the most common demyelinating disease of man with over 400,000 cases in the United States and over 2.5 million cases worldwide. There are over 64,000 citations in Pubmed dating back as far as 1887. Much has been learned over the past 129 years with a recent burst in therapeutic options (mostly anti-inflammatory) with newer medications in development that are neuroprotective and/or neuroreparative. However, with all these advancements the cause of MS remains elusive. There is a clear interplay of genetic, immunologic, and environmental factors that influences both the development and progression of this disorder. This chapter will give a brief overview of the history and pathogenesis of MS with attention to how host immune responses in genetically susceptible individuals contribute to the MS disease process. In addition, we will explore the role of infectious agents in MS as potential “triggers” of disease. Models of virus-induced demyelination will be discussed, with an emphasis on the recent interest in human herpesviruses and the role they may play in MS disease pathogenesis. Although we remain circumspect as to the role of any microbial pathogen in MS, we suggest that only through well-controlled serological, cellular immune, molecular, and animal studies we will be able to identify candidate agents. Ultimately, clinical interventional trials that either target a specific pathogen or class of pathogens will be required to make definitive links between the suspected agent and MS.
format Online
Article
Text
id pubmed-7122906
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-71229062020-04-06 Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis Soldan, Samantha S. Jacobson, Steven Neurotropic Viral Infections Article Multiple Sclerosis (MS) is the most common demyelinating disease of man with over 400,000 cases in the United States and over 2.5 million cases worldwide. There are over 64,000 citations in Pubmed dating back as far as 1887. Much has been learned over the past 129 years with a recent burst in therapeutic options (mostly anti-inflammatory) with newer medications in development that are neuroprotective and/or neuroreparative. However, with all these advancements the cause of MS remains elusive. There is a clear interplay of genetic, immunologic, and environmental factors that influences both the development and progression of this disorder. This chapter will give a brief overview of the history and pathogenesis of MS with attention to how host immune responses in genetically susceptible individuals contribute to the MS disease process. In addition, we will explore the role of infectious agents in MS as potential “triggers” of disease. Models of virus-induced demyelination will be discussed, with an emphasis on the recent interest in human herpesviruses and the role they may play in MS disease pathogenesis. Although we remain circumspect as to the role of any microbial pathogen in MS, we suggest that only through well-controlled serological, cellular immune, molecular, and animal studies we will be able to identify candidate agents. Ultimately, clinical interventional trials that either target a specific pathogen or class of pathogens will be required to make definitive links between the suspected agent and MS. 2016-04-08 /pmc/articles/PMC7122906/ http://dx.doi.org/10.1007/978-3-319-33189-8_6 Text en © Springer International Publishing Switzerland 2016 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Soldan, Samantha S.
Jacobson, Steven
Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis
title Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis
title_full Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis
title_fullStr Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis
title_full_unstemmed Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis
title_short Virus-Induced Demyelination: The Case for Virus(es) in Multiple Sclerosis
title_sort virus-induced demyelination: the case for virus(es) in multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122906/
http://dx.doi.org/10.1007/978-3-319-33189-8_6
work_keys_str_mv AT soldansamanthas virusinduceddemyelinationthecaseforvirusesinmultiplesclerosis
AT jacobsonsteven virusinduceddemyelinationthecaseforvirusesinmultiplesclerosis